Kala Bio Inc. has announced its financial results for the first quarter of 2025, ending March 31. The company reported a net loss of $8.9 million, a decrease from the $11.8 million net loss recorded in the same period of 2024. The operating loss for the quarter was $10.7 million, compared to $11.9 million in the first quarter of 2024. General and administrative expenses were $4.6 million, down from $5.4 million, primarily due to reduced employee-related costs. Research and development expenses were $6.1 million, slightly lower than the $6.4 million spent in the same period last year, largely due to decreased medical affairs-related costs for the development of KPI-012. On the business front, Kala Bio is progressing with its Phase 2b CHASE trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED), with topline data expected in the third quarter of 2025. The company aims for these results to potentially support a Biologics License Application $(BLA.AU)$ submission. As of March 31, 2025, Kala Bio's cash resources stood at $42.2 million, which are projected to fund operations into the first quarter of 2026.